Papillary adenocarcinoma of the endometrium: a retrospective study of stage I and II disease.
A retrospective study was undertaken to determine the survival of patients with stages I and II serous papillary adenocarcinoma of the endometrium. Twenty-eight patients were evaluable. The patients were treated by a variety of methods that included irradiation only, surgery only, combined irradiation and surgery, and chemotherapy. Eighteen patients had stage I disease and 10 patients had stage II disease. The 2-year survival rate was 16.6% for stage I patients and 40% for stage II patients. The overall 2-year survival rate was 28% for both groups of patients.
Chapman
G W
GW
Division of Gynecologic Oncology, Howard University Hospital, Washington, DC 20060.
D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D018283:Cystadenocarcinoma, Papillary / Q000401:mortality* / Q000628:therapy*; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000628:therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate